QIA Participates in Investment in OncoResponse

Posted on 09/11/2018


Seattle-based OncoResponse, which focuses on anti-cancer therapies, raised US$ 40 million in a Series B round. The Series B round was led by RiverVest Venture Partners. Other investors in the Series B round include the Qatar Investment Authority (QIA), Redmile Group, Alexandria Venture Investments, ARCH Venture Partners, HT Family Office, Canaan Partners, Helsinn Investment Fund, […]